NanoViricides, Inc. (OTCMKTS:NNVC) Continues Upward, Faces End of Week Challenge
There seems to be momentum gathering for NanoViricides, Inc. (OTCMKTS:NNVC), despite the lack of new press releases and promotions. The stock added another 13% on Tuesday to stand at $1.32.Volumes were above $1.63 million. Thus, the stock has gradually gained a dollar since March this year, and without negative news may hope to keep up the good levels. 
The new orphan drug status means NNVC would receive tax credits and other preferences for taking the time to create a therapy for a significant, though rare threat, dengue fever. The creation of such a drug does not promise mass marketing success, for which other pharmaceutical companies strive. So far, NNVC has shown it could use a financial booster, given its financial situation: 
- $15.4 million cash
- $17.8 million total assets
- $7.7 million total liabilities
- $3.6 million quarterly net loss
- $36 million loss for 96 months
Still, despite those results, momentum may serve to drive NNVC for a while more, as the company has strong indicators it can continue as more than a one-off wonder. And if NNVC shares its press releases, it may keep up the interest. In the shorter term, NNVC still has to survive the end of the week, and the possible backturn on Friday.
The biopharmaceutical sector is a staple in the group of most actively traded penny stocks, so another look at close selections is useful. In the past days, Advanced Cell Technology, Inc. (OTCBB:ACTC) is more active, but mostly because it is being unloaded after a rapid rise. The unloading is faster now, with dollar volumes above $1.24, that depressed the price to 6 cents.
With a riskier model, Anavex Life Sciences, Inc. (OTCMKTS:AVXL) is moving way more erratically, currently bearing down below 70 cents. But the recent spike took the ticker up 50% in three days of very robust buying volumes.
Whatever ticker you choose, keep in mind that sentiment is quite sensitive to news on the company’s future developments, even when the news is just tentative. Some companies propose therapies that are way more feasible than others. It is best to decide based on your own research, and only invest sums that you can afford to lose in part or in whole in case of a deep correction.
